# A Study to Evaluate the Safety and Efficacy of Polatuzumab Vedotin in Combination With Rituximab, Gemcitabine and Oxaliplatin Compared to Rituximab, Gemcitabine and Oxaliplatin Alone in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

> **NCT04182204** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 270 (actual)

## Conditions studied

- Diffuse Large B-Cell Lymphoma

## Interventions

- **DRUG:** Polatuzumab Vedotin
- **DRUG:** Rituximab
- **DRUG:** Gemcitabine
- **DRUG:** Oxaliplatin

## Key facts

- **NCT ID:** NCT04182204
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-02-07
- **Primary completion:** 2024-11-29
- **Final completion:** 2024-11-29
- **Target enrollment:** 270 (ACTUAL)
- **Last updated:** 2025-12-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04182204

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04182204, "A Study to Evaluate the Safety and Efficacy of Polatuzumab Vedotin in Combination With Rituximab, Gemcitabine and Oxaliplatin Compared to Rituximab, Gemcitabine and Oxaliplatin Alone in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma". Retrieved via AI Analytics 2026-06-29 from https://api.ai-analytics.org/clinical/NCT04182204. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*